New York State Common Retirement Fund Purchases 2,308 Shares of Dermira Inc (DERM)

New York State Common Retirement Fund boosted its position in Dermira Inc (NASDAQ:DERM) by 4.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,993 shares of the biopharmaceutical company’s stock after buying an additional 2,308 shares during the quarter. New York State Common Retirement Fund owned approximately 0.12% of Dermira worth $1,350,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its stake in Dermira by 2,220.7% in the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 3,975 shares in the last quarter. SG Americas Securities LLC grew its stake in Dermira by 66.8% in the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 2,203 shares in the last quarter. Legal & General Group Plc grew its stake in Dermira by 40.9% in the second quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,803 shares in the last quarter. Ardsley Advisory Partners bought a new position in Dermira in the second quarter valued at approximately $291,000. Finally, Bank of Nova Scotia bought a new position in Dermira in the second quarter valued at approximately $318,000. 99.47% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have weighed in on the company. Cantor Fitzgerald restated a “buy” rating and issued a $45.00 price target on shares of Dermira in a research note on Tuesday, September 26th. Needham & Company LLC restated a “buy” rating and issued a $46.00 price target on shares of Dermira in a research note on Sunday, September 17th. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Guggenheim restated a “buy” rating and issued a $30.00 price target on shares of Dermira in a research note on Thursday, December 14th. Finally, Mizuho reiterated a “buy” rating and set a $43.00 target price (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Three analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $41.00.

In other news, CEO Thomas G. Wiggans sold 5,000 shares of Dermira stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eugene A. Bauer sold 3,000 shares of Dermira stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $27.34, for a total value of $82,020.00. The disclosure for this sale can be found here. Insiders have sold a total of 26,700 shares of company stock valued at $751,456 over the last quarter. 13.30% of the stock is currently owned by corporate insiders.

Dermira Inc (NASDAQ:DERM) opened at $28.71 on Thursday. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68. Dermira Inc has a one year low of $21.35 and a one year high of $38.75. The company has a market capitalization of $1,180.00, a P/E ratio of -4.61 and a beta of 0.80.

COPYRIGHT VIOLATION NOTICE: “New York State Common Retirement Fund Purchases 2,308 Shares of Dermira Inc (DERM)” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.chaffeybreeze.com/2018/01/04/new-york-state-common-retirement-fund-purchases-2308-shares-of-dermira-inc-derm.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply